UY25103A1 - Composición para el tratamiento de diabetes mellitus - Google Patents

Composición para el tratamiento de diabetes mellitus

Info

Publication number
UY25103A1
UY25103A1 UY25103A UY25103A UY25103A1 UY 25103 A1 UY25103 A1 UY 25103A1 UY 25103 A UY25103 A UY 25103A UY 25103 A UY25103 A UY 25103A UY 25103 A1 UY25103 A1 UY 25103A1
Authority
UY
Uruguay
Prior art keywords
treatment
diabetes mellitus
composition
insulin
amount
Prior art date
Application number
UY25103A
Other languages
English (en)
Inventor
Dr R Edwin Buckingham
Dr S Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10816177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25103(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY25103A1 publication Critical patent/UY25103A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones para el tratamiento de la diabetes mellitus y las condiciones asociadas con la misma en un mamífero, que comprende una cantidad efectiva, no tóxica y farmacéuticamente aceptable de un sensibilizador a insulina y una cantidad submáxima de un secretagogo de insulina.
UY25103A 1997-07-18 1998-07-17 Composición para el tratamiento de diabetes mellitus UY25103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715306A GB9715306D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
UY25103A1 true UY25103A1 (es) 2000-12-29

Family

ID=10816177

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25103A UY25103A1 (es) 1997-07-18 1998-07-17 Composición para el tratamiento de diabetes mellitus

Country Status (41)

Country Link
EP (1) EP0998291B2 (es)
JP (2) JP2001510158A (es)
KR (1) KR100680667B1 (es)
CN (1) CN1264302A (es)
AP (1) AP1318A (es)
AR (2) AR016768A1 (es)
AT (1) ATE366577T1 (es)
AU (1) AU743269B2 (es)
BG (1) BG64892B1 (es)
BR (1) BR9810904A (es)
CA (1) CA2297115C (es)
CO (1) CO4940422A1 (es)
CY (1) CY1107745T1 (es)
CZ (1) CZ302668B6 (es)
DE (1) DE69838066T3 (es)
DK (1) DK0998291T4 (es)
DZ (1) DZ2564A1 (es)
EA (1) EA003303B1 (es)
ES (1) ES2290989T5 (es)
GB (1) GB9715306D0 (es)
HK (1) HK1029272A1 (es)
HU (1) HU229119B1 (es)
ID (1) ID24198A (es)
IL (1) IL134045A0 (es)
IN (1) IN189035B (es)
MA (1) MA26522A1 (es)
MY (1) MY138246A (es)
NO (1) NO326356B1 (es)
NZ (3) NZ520652A (es)
OA (1) OA11632A (es)
PE (1) PE99799A1 (es)
PL (2) PL338127A1 (es)
PT (1) PT998291E (es)
SI (1) SI0998291T2 (es)
SK (2) SK288053B6 (es)
TR (1) TR200000135T2 (es)
TW (1) TW586926B (es)
UA (1) UA70302C2 (es)
UY (1) UY25103A1 (es)
WO (1) WO1999003476A1 (es)
ZA (1) ZA986365B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897547A1 (en) * 1999-07-13 2008-03-12 Medicure Inc. Use of pyridoxal phosphate derivatives for the treatment of diabetes and related complications
EP1832291A3 (en) * 1999-07-13 2009-11-04 Medicure Inc. use of pyridoxal phosphate for the treatment of diabetes and related complications
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
WO2005041962A1 (en) * 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
UA91729C2 (ru) 2005-12-22 2010-08-25 Такеда Фармасьютикал Компани Лимитед Твердая форма лекарственного препарата

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
ES2089474T3 (es) * 1991-08-16 1996-10-01 Sandoz Ltd Inhalador para la administracion de sustancias en polvo.
WO1993003724A1 (en) * 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
AR016768A1 (es) 2001-08-01
MY138246A (en) 2009-05-29
PL199125B1 (pl) 2008-08-29
EP0998291A1 (en) 2000-05-10
CA2297115A1 (en) 1999-01-28
DK0998291T3 (da) 2007-11-05
CZ2000173A3 (en) 2001-05-16
PT998291E (pt) 2007-10-11
IL134045A0 (en) 2001-04-30
IN189035B (es) 2002-12-07
CZ302668B6 (cs) 2011-08-24
PL338127A1 (en) 2000-09-25
OA11632A (en) 2004-11-22
AP2000001734A0 (en) 2000-03-31
ES2290989T3 (es) 2008-02-16
DE69838066T3 (de) 2012-03-29
SK602000A3 (en) 2000-07-11
DE69838066D1 (de) 2007-08-23
DZ2564A1 (fr) 2003-02-15
EA200000141A1 (ru) 2000-08-28
JP2005247865A (ja) 2005-09-15
BR9810904A (pt) 2000-09-26
GB9715306D0 (en) 1997-09-24
MA26522A1 (fr) 2004-12-20
JP2001510158A (ja) 2001-07-31
NO20000229D0 (no) 2000-01-17
HUP0003634A3 (en) 2003-04-28
HUP0003634A2 (hu) 2001-07-30
SI0998291T1 (sl) 2007-12-31
SK287823B6 (sk) 2011-11-04
AP1318A (en) 2004-10-22
HU229119B1 (en) 2013-08-28
TR200000135T2 (tr) 2000-05-22
CY1107745T1 (el) 2013-04-18
KR20010021948A (ko) 2001-03-15
SI0998291T2 (sl) 2011-10-28
AU8448798A (en) 1999-02-10
BG64892B1 (bg) 2006-08-31
PE99799A1 (es) 1999-12-22
CA2297115C (en) 2010-02-23
SK288053B6 (sk) 2013-03-01
ID24198A (id) 2000-07-13
WO1999003476A1 (en) 1999-01-28
AR019331A2 (es) 2002-02-13
DE69838066T2 (de) 2008-03-20
EA003303B1 (ru) 2003-04-24
TW586926B (en) 2004-05-11
NO326356B1 (no) 2008-11-17
NO20000229L (no) 2000-01-17
EP0998291B2 (en) 2011-07-06
EP0998291B1 (en) 2007-07-11
UA70302C2 (uk) 2004-10-15
NZ520652A (en) 2004-06-25
HK1029272A1 (en) 2001-03-30
KR100680667B1 (ko) 2007-02-09
BG104139A (en) 2000-11-30
ATE366577T1 (de) 2007-08-15
CO4940422A1 (es) 2000-07-24
DK0998291T4 (da) 2011-09-26
NZ501256A (en) 2002-09-27
CN1264302A (zh) 2000-08-23
ZA986365B (en) 2000-01-17
AU743269B2 (en) 2002-01-24
NZ515555A (en) 2002-09-27
ES2290989T5 (es) 2011-11-11

Similar Documents

Publication Publication Date Title
ATE314393T1 (de) Verzögerte freigabe von insulinotropin (glp-1)
CY1107643T1 (el) Αντιμετωπιση του διαβητη με θειαζολιδινοδιονη και μετφορμινη
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
CO4940454A1 (es) Nuevo metodo de tratamiento
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
BR9915214A (pt) Combinações contendo um beta-agonista e umagente anti-diabético adicional
ECSP982593A (es) Nuevo metodo de tratamiento vi
ECSP982591A (es) Nuevo metodo de tratamiento iv
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
ECSP982541A (es) Nuevo metodo de tratamiento ii
UY25801A1 (es) Procedimiento para preparar composiciones para el tratamiento de diabetes.
ECSP982542A (es) Nuevo metodo de tratamiento iii
ECSP982592A (es) Nuevo metodo de tratamiento v
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982534A (es) Nuevo metodo de tratamiento
CO5270004A1 (es) Composiciones farmaceuticas con agente del tipo biguanida para tratamientos en diabetes

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20180717